Multi-arm polymer prodrugs
View Patent ↗Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
1. A multi-arm polymer prodrug having the structure:
wherein
R is an organic radical possessing from 3 to 25 carbon atoms,
Q is a linker, wherein R, when taken together with Q to form R(-Q-) q , is a residue of a polyol or a polythiol after removal of “q” hydroxyl or thiol protons, respectively, to form a point of attachment for POLY 1 ,
POLY 1 is a water-soluble polymer selected from the group consisting of poly(alkylene glycol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxylalkyl-methacrylamide), poly(hydroxyalkyl-methacrylate), poly(a-hydroxy acid), poly(acrylic acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), and copolymers or terpolymers thereof,
D is a small molecule anticancer drug, with the proviso that the drug is not paclitaxel or docetaxel, and q has a value from 3 to 10.
2. The multi-arm polymer prodrug of claim 1 , wherein R possesses a number of carbon atoms selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, and 10.
3. The multi-arm polymer prodrug of claim 1 , wherein R is linear or cyclic.
4. The multi-armed polymer prodrug of claim 1 , wherein R, taken together with Q to form R(-Q-) q , is a residue of glycerol, trimethylolpropane, pentaerythritol, sorbitol, or glycerol oligomers after removal of “q” hydroxyl protons.
5. The multi-armed polymer prodrug of claim 1 , wherein Q is a sulfur atom.
6. The multi-armed polymer prodrug of claim 1 , wherein Q comprises a heteroatom in addition to said polyol oxygen or said polythiol sulfur.
7. The multi-armed polymer prodrug of claim 1 , wherein Q contains from 1 to 10 atoms.
8. The multi-armed polymer prodrug of claim 1 , wherein Q is an oxygen atom.
9. The multi-armed polymer prodrug of claim 1 , wherein POLY 1 is a polyethylene glycol.
10. The multi-armed polymer prodrug of claim 9 , wherein POLY 1 is linear.
11. The multi-armed polymer prodrug of claim 1 , wherein the nominal average molecular weight of POLY 1 ranges from 200 to 30,000 daltons.
12. The multi-armed polymer prodrug of claim 1 , wherein the nominal average molecular weight of POLY 1 ranges from 500 to 20,000 daltons.
13. The multi-armed polymer prodrug of claim 1 , wherein the value of q is selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, and 10.
14. The multi-armed polymer prodrug of claim 1 , wherein each of said “q” polymer arms
is the same.
15. A pharmaceutical composition comprising a multi-arm polymer prodrug of claim 1 and a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 15 in solid form.
17. The multi-armed polymer prodrug of claim 13 , wherein the value of q is 4.
18. The multi-armed polymer prodrug of claim 4 , wherein R, taken together with Q to form R(-Q-) q , is a residue of pentaerythritol after removal of “q” hydroxyl protons.
19. The multi-armed polymer prodrug of claim 1 , wherein:
POLY 1 is a linear polyethylene glycol;
R, taken together with Q to form R(-Q-) q , is a residue of pentaerythritol after removal of “q” hydroxyl protons; and
q has a value of 4.